Not Tagged
Not Tagged
['bcsm', 'breast']
her3 adc in #bcsm. follow-up 32 mo. in heavily pretreated population, responses seen to her3-dxd across all breast cancer subtypes. 10% discontinuation. ild seen in 7%, but mostly grade 1-2.
presented by ian krop of #asco22 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.